Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Gold

Showing results (231-240 of 234) with videos related to

Pageof 24
Sort By:
You have reached the last page of results.This site can display upto 234 results.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|October 16, 2012
The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: the next therapeutic frontier)Adam L Boxer, Michael Gold, Edward Huey, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|August 30, 2012
2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management, , , et al.
Nature Medicine|February 26, 2020
TMEM30A loss-of-function mutations drive lymphomagenesis and confer therapeutically exploitable vulnerability in B-cell lymphomaDaisuke Ennishi, Shannon Healy, Ali Bashashati, et al.
Nature|December 13, 2002
Overview of the Alliance for Cellular SignalingAlfred G Gilman, Melvin I Simon, Henry R Bourne, et al.
Pageof 24

Showing results (231-240 of 234) with videos related to

Sort By:
Pageof 24
You have reached the last page of results.This site can display upto 234 results.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|October 16, 2012
The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: the next therapeutic frontier)Adam L Boxer, Michael Gold, Edward Huey, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|August 30, 2012
2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management, , , et al.
Nature Medicine|February 26, 2020
TMEM30A loss-of-function mutations drive lymphomagenesis and confer therapeutically exploitable vulnerability in B-cell lymphomaDaisuke Ennishi, Shannon Healy, Ali Bashashati, et al.
Nature|December 13, 2002
Overview of the Alliance for Cellular SignalingAlfred G Gilman, Melvin I Simon, Henry R Bourne, et al.
Pageof 24